Pharmacia
This article was originally published in The Tan Sheet
Executive Summary
Nicorette "still in its infancy in many significant countries" such as Germany, Italy, Spain, where sales not yet on par with smaller Ireland market, VP-Global Specialty Operations Stephen MacMillan tells investors Nov. 29. Sales are up 28% for first nine months of 2001, spurred by new global marketing campaign, reacquisition of brand from Canadian distributor and recent OTC switch in Japan, where sales are $1 mil. per week. MacMillan also heralded 8.5% sales increase for Pharmacia's global consumer healthcare - about triple the industry average - and 13% sales growth in North America...
You may also be interested in...
Nicorette International Growth Integral To Pfizer OTC Strength – Hassan
Nicorette gum will be one of the driving forces behind Pfizer's international consumer business, Pharmacia Chairman & CEO Fred Hassan predicted July 15
Nicorette Global Sales Jump 62% In Q4 With International Expansion
Pharmacia's Nicorette smoking cessation franchise generated a 37% increase in global sales in 2001, leading total consumer health to double-digit revenue gains
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.